TY - JOUR
T1 - The case for tailored prostate cancer screening
T2 - An NCCN perspective
AU - McDonald, Michelle L.
AU - Parsons, J. Kellogg
N1 - Publisher Copyright:
© National Comprehensive Cancer Network, Inc. 2015, All rights reserved.
PY - 2015/12/1
Y1 - 2015/12/1
N2 - A preponderance of clinical evidence supports a significant public health benefit for screening and early detection of prostate cancer in selected men. The challenge lies in maximizing early diagnosis of potentially aggressive but curable disease while minimizing diagnosis and treatment of indolent disease. A tailored approach to population screening in appropriately counseled men, using an evidence-based strategy with judicious prostate-specific antigen (PSA) testing, will reduce prostate-cancer mortality yet limit overdetection of clinically insignificant disease. Use of newer biomarkers that increase specificity for prostate cancer detection, including percentage of free PSA, 4Kscore, prostate health index, prostate cancer antigen 3, and multiparametric MRI may be considered under certain circumstances.
AB - A preponderance of clinical evidence supports a significant public health benefit for screening and early detection of prostate cancer in selected men. The challenge lies in maximizing early diagnosis of potentially aggressive but curable disease while minimizing diagnosis and treatment of indolent disease. A tailored approach to population screening in appropriately counseled men, using an evidence-based strategy with judicious prostate-specific antigen (PSA) testing, will reduce prostate-cancer mortality yet limit overdetection of clinically insignificant disease. Use of newer biomarkers that increase specificity for prostate cancer detection, including percentage of free PSA, 4Kscore, prostate health index, prostate cancer antigen 3, and multiparametric MRI may be considered under certain circumstances.
UR - http://www.scopus.com/inward/record.url?scp=84950980583&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84950980583&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2015.0183
DO - 10.6004/jnccn.2015.0183
M3 - Review article
C2 - 26656524
AN - SCOPUS:84950980583
SN - 1540-1405
VL - 13
SP - 1576
EP - 1583
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 12
ER -